Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Diabetic Macular Edema/Diabetic Retinopathy | Unmet Need | Diabetic Macular Edema | US/FR/DE/UK | 2021

Login to access report north_east
Contact sales account_box

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-leading Eylea. Because these therapies require regular injections to be effective, they present a major delivery burden that often impacts patient compliance. The corticosteroid implants Ozurdex (AbbVie) and Iluvien (Alimera Sciences) provide a longer duration of action between doses but are associated with side effects that relegate them to later-line treatment. Therefore, unmet need remains for therapies that provide strong efficacy for improving visual acuity with less-frequent dosing.

QUESTIONS ANSWERED

  • What are the key treatment drivers and goals for DME that influence ophthalmologists’ choice of therapies?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities in the DME market?
  • How do ophthalmologists perceive the performance of current therapies on key treatment drivers and goals for DME?
  • What are the prevailing areas of market opportunity in the treatment of DME? Will emerging therapies, such as Novartis’s Beovu or Roche’s faricimab, fulfill these unmet needs?
  • What trade-offs are acceptable to U.S. and European ophthalmologists for a hypothetical DME drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in February 2021

Key companies: Roche / Genentech, Regeneron / Bayer, Novartis, AbbVie (Allergan), Alimera Sciences, Kodiak Sciences

Key drugs: Lucentis, Eylea, Avastin, Ozurdex, Iluvien, Beovu, ranibizumab port delivery system, high-dose aflibercept, KSI-301, faricimab

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
north_east
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
north_east
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
north_east
Report
Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (US)
Male hypogonadism (low testosterone, or low T) is a condition characterized by impaired spermatogenesis and low serum testosterone. Most cases are secondary, driven by aging or comorbidities (e.g…
north_east
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east